JPWO2020058504A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020058504A5 JPWO2020058504A5 JP2021514550A JP2021514550A JPWO2020058504A5 JP WO2020058504 A5 JPWO2020058504 A5 JP WO2020058504A5 JP 2021514550 A JP2021514550 A JP 2021514550A JP 2021514550 A JP2021514550 A JP 2021514550A JP WO2020058504 A5 JPWO2020058504 A5 JP WO2020058504A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- patient
- corneal area
- corneal
- area
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 24
- 230000035807 sensation Effects 0.000 claims 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 4
- 206010065062 Meibomian gland dysfunction Diseases 0.000 claims 4
- 230000002123 temporal effect Effects 0.000 claims 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 3
- 238000010186 staining Methods 0.000 claims 3
- 208000023715 Ocular surface disease Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 206010047513 Vision blurred Diseases 0.000 claims 2
- 230000007803 itching Effects 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 1
- 239000000607 artificial tear Substances 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 230000008447 perception Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18196126 | 2018-09-22 | ||
| EP18196126.9 | 2018-09-22 | ||
| EP18198440 | 2018-10-03 | ||
| EP18198440.2 | 2018-10-03 | ||
| EP18202041.2 | 2018-10-23 | ||
| EP18202041 | 2018-10-23 | ||
| PCT/EP2019/075406 WO2020058504A1 (en) | 2018-09-22 | 2019-09-20 | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500461A JP2022500461A (ja) | 2022-01-04 |
| JPWO2020058504A5 true JPWO2020058504A5 (https=) | 2022-09-27 |
| JP2022500461A5 JP2022500461A5 (https=) | 2022-09-27 |
Family
ID=68240699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514550A Pending JP2022500461A (ja) | 2018-09-22 | 2019-09-20 | 眼表面の損傷および乾燥の症状の治療のための眼科用組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210346313A1 (https=) |
| EP (1) | EP3852734A1 (https=) |
| JP (1) | JP2022500461A (https=) |
| KR (1) | KR20210080388A (https=) |
| CN (1) | CN112739335A (https=) |
| AU (2) | AU2019342426A1 (https=) |
| CA (1) | CA3111873A1 (https=) |
| IL (1) | IL281516A (https=) |
| PH (1) | PH12021550621A1 (https=) |
| SG (1) | SG11202102818YA (https=) |
| WO (1) | WO2020058504A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108348777B (zh) | 2015-09-30 | 2020-04-28 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| USRE50060E1 (en) | 2016-06-23 | 2024-07-30 | Novaliq Gmbh | Topical administration method |
| ES2969758T3 (es) | 2016-09-22 | 2024-05-22 | Novaliq Gmbh | Composiciones farmacéuticas para usar en la terapia de la blefaritis |
| US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| PT3399962T (pt) | 2016-12-23 | 2020-09-03 | Novaliq Gmbh | Composição oftálmica para o tratamento da doença do olho seco |
| CA3058097C (en) | 2017-04-21 | 2024-01-02 | Novaliq Gmbh | Iodine compositions |
| KR20200059272A (ko) | 2017-09-27 | 2020-05-28 | 노바리크 게엠베하 | 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물 |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| EP3758676A1 (en) | 2018-03-02 | 2021-01-06 | Novaliq GmbH | Pharmaceutical compositions comprising nebivolol |
| KR102882058B1 (ko) | 2018-03-28 | 2025-11-07 | 노바리크 게엠베하 | 티몰롤을 포함하는 약제학적 조성물 |
| JP2021522219A (ja) | 2018-04-27 | 2021-08-30 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| CN113710228A (zh) | 2019-02-13 | 2021-11-26 | 诺瓦利克有限责任公司 | 用于治疗眼部新生血管形成的组合物和方法 |
| US12419933B2 (en) | 2019-09-06 | 2025-09-23 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| EP1494681A4 (en) * | 2002-04-16 | 2008-08-06 | Collagenex Pharm Inc | PROCESS FOR THE SIMULTANEOUS TREATMENT OF OCULAR ROSACEA AND ACNE ROSACEA |
| US10105441B2 (en) * | 2007-08-16 | 2018-10-23 | The Schepens Eye Research Institute, Inc. | Method for inhibiting or reducing dry eye disease by IL-1Ra |
| EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| CN113679697A (zh) | 2012-09-12 | 2021-11-23 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| DK3181119T3 (da) * | 2012-09-12 | 2019-09-16 | Novaliq Gmbh | Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca |
| CN106999402B (zh) * | 2014-10-09 | 2020-10-27 | 梅迪普罗都司股份有限公司 | 睫毛用清洗剂 |
| CN108348777B (zh) * | 2015-09-30 | 2020-04-28 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| ES2969758T3 (es) * | 2016-09-22 | 2024-05-22 | Novaliq Gmbh | Composiciones farmacéuticas para usar en la terapia de la blefaritis |
| CN111182893A (zh) * | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
-
2019
- 2019-09-20 EP EP19786907.6A patent/EP3852734A1/en active Pending
- 2019-09-20 US US17/278,585 patent/US20210346313A1/en active Pending
- 2019-09-20 CA CA3111873A patent/CA3111873A1/en active Pending
- 2019-09-20 CN CN201980062052.2A patent/CN112739335A/zh active Pending
- 2019-09-20 SG SG11202102818YA patent/SG11202102818YA/en unknown
- 2019-09-20 JP JP2021514550A patent/JP2022500461A/ja active Pending
- 2019-09-20 WO PCT/EP2019/075406 patent/WO2020058504A1/en not_active Ceased
- 2019-09-20 AU AU2019342426A patent/AU2019342426A1/en not_active Abandoned
- 2019-09-20 KR KR1020217011860A patent/KR20210080388A/ko active Pending
-
2021
- 2021-03-15 IL IL281516A patent/IL281516A/en unknown
- 2021-03-18 PH PH12021550621A patent/PH12021550621A1/en unknown
-
2025
- 2025-06-06 US US19/231,354 patent/US20250295607A1/en active Pending
- 2025-06-10 AU AU2025204313A patent/AU2025204313A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500461A5 (https=) | ||
| JP2024116245A5 (https=) | ||
| JPWO2020058504A5 (https=) | ||
| Yang et al. | A clinical study of the efficacy of topical corticosteroids on dry eye | |
| Federici | The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease | |
| JPWO2020074697A5 (https=) | ||
| JP2015509500A5 (https=) | ||
| US20220257593A1 (en) | Carabachol-bromonidine formulation to enhance anti-presbyopia effects | |
| Toda et al. | Excimer laser photorefractive keratectomy for patients with contact lens intolerance caused by dry eye. | |
| JP6267003B2 (ja) | ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤 | |
| US20230338307A1 (en) | Prophylactic agent, ameliorating agent, and therapeutic agent for dry eye | |
| Voss et al. | Non-infectious and non-hereditary diseases of the corneal epithelium | |
| WO2012015996A2 (en) | Preservative free bimatoprost solutions | |
| Franks et al. | A 6-week, double-masked, paralle-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0: 005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension | |
| EP3407879B1 (en) | Ophthalmic gabapentin for the treatment of corneal ulcers | |
| El Fekih et al. | Successful management of dry eye disease with a new eye drop formulation combining hyaluronic acid, trehalose, and N-acetyl-aspartyl-glutamic acid (NAAGA) | |
| JP2022529823A (ja) | ドライアイの治療に使用可能な組成物および方法 | |
| US20240216375A1 (en) | Use of sympathetic activation inhibitor and/or alpha 1-adrenergic receptor inhibitor in preparing medicine for treating dry eyes | |
| RU2021107208A (ru) | Офтальмологические композиции для лечения повреждения поверхности глаза и симптомов сухости глаз | |
| Zamir et al. | Neurotrophic corneal endothelial failure complicating acute Horner syndrome | |
| KR20220131018A (ko) | 무막줄기세포추출물을 포함하는 안구건조증 치료용 조성물 및 이에 의해 제조된 점안액 | |
| Pacella et al. | The combination latanoprost-timolol versus twice daily 0.50% timolol administration either associated or not with latanoprost: efficacy and tolerability in the primary open-angle glaucoma | |
| Brooks | Hypertensive iridocyclitis and glaucoma of horses | |
| Tripathy et al. | Corneal changes in diabetes mellitus | |
| Chen et al. | The biomechanical properties of the cornea of patients with glaucoma treated with anti-glaucoma topical medications |